Abstract
ACTH-secreting pheochromocytoma is a very rare cause of Cushing’s syndrome, with a high morbidity and mortality risk due to both cortisol and catecholamines excess. We report the case of a 45-year-old female patient with a 3 cm, high-density, left adrenal mass, diagnosed as an ACTH-secreting pheochromocytoma. The biochemical sensitivity of the tumor to somatostatin analogues was tested by a 100 μg s.c. octreotide administration, which led to an ACTH and cortisol reduction of 50 and 25% respectively. In addition to alpha and beta blockers, preoperative approach to laparoscopic adrenalectomy included octreotide, a somatostatin analogue, together with ketoconazole, in order to achieve an adequate pre-surgical control of cortisol release. Histopathological assessment confirmed an ACTH-secreting pheochromocytoma expressing type 2 and 5 somatostatin receptors (SSTR-2 and-5).
Cite
CITATION STYLE
Rossini, A., Perticone, F., Frosio, L., Lena, M. S., & Lanzi, R. (2019). Somatostatin analog challenge test in the pre-surgical management of acth-secreting pheochromocytoma. Endocrinology, Diabetes and Metabolism Case Reports, 2019(1). https://doi.org/10.1530/EDM-19-0123
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.